BILTHOVEN, The Netherlands--(BUSINESS WIRE)--Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD). Additionally, the company has established its Scientific Advisory Board (SAB), comprised of experts in diseases with high unmet medical need, as well as the rapidly expanding field of RNA delivery.
Marco Timmers has cultivated a career spanning over 25 years in pharmaceutical R&D and has held various leadership positions at international biotechnology and pharmaceutical corporations. Before joining Sapreme, he was CEO of Byondis (formerly Synthon Biopharmaceuticals), a clinical-stage biopharmaceutical company developing Antibody-Drug Conjugates (ADCs) targeting intractable cancers and auto-immune diseases. During his time at Byondis, Dr. Timmers also served as Chief Scientific Officer, guiding the company’s clinical strategies and growth. Before that, he held various positions of increasing responsibility at Organon, Schering-Plough and MSD, including Head of Medicinal Chemistry, Proof-of-Concept Team Leader and Site Lead Women’s Health and Endocrinology. He holds a MSc and a PhD in bio-organic chemistry from Leiden University in The Netherlands.
“Sapreme’s endosomal escape technology holds great potential in enabling much-needed improved intracellular delivery for next-generation large molecule drugs. I look forward to working with the team at Sapreme to further advance this innovative platform and accelerate our pipeline of RNA therapeutic candidates addressing a range of genetically driven diseases,” said Marco Timmers, Chief Executive Officer of Sapreme.
Jeanne Bolger is an experienced biopharma senior executive with extensive business development and investment expertise over her 35 years in the pharmaceutical sector. She served on the board of over a dozen life sciences companies during her 10 years as Vice President of Venture Investing at Johnson & Johnson Innovation-JJDC. Dr. Bolger’s drug development and commercial expertise spans numerous therapeutic fields, including oncology, neurology, psychiatry, respiratory, immunology, infectious disease and vaccines, and cell and gene therapy. She is a Non-Executive Board Director of Life Healthcare. She is also the Chair of the Board at ExeVir and at Astrivax. Dr. Bolger holds an MB BCh in Medicine from University College Dublin. She has been a member of the Sapreme Board of Directors since July 2023.
“Marco’s deep R&D and leadership expertise, coupled with the newly formed SAB places Sapreme in an optimal position to deliver on its upcoming corporate and clinical goals,” commented Jeanne Bolger, Chair of the Board of Directors of Sapreme. “It is a great pleasure to support this dynamic team on its path to overcoming significant hurdles in next-generation therapeutics.”
Scientific Advisory Board Appointments
|Sapreme has established a SAB to guide the company as it advances its preclinical candidates toward clinical proof-of-concept. The new members of the Sapreme SAB include:
Steven Dowdy, PhD
Steven Dowdy is professor of cellular and molecular medicine at the University of California San Diego School of Medicine and is a leading expert in the field of endosomal escape. Dr. Dowdy has been advising biotech and pharmaceutical companies for 35 years, and he is currently a member of five biotech SABs. His research over the last 30 years has primarily focused on the delivery of macromolecular therapeutics, including siRNAs, ASOs, peptides, and proteins, and developing new chemistries to tackle the issue of rate-limiting endosomal escape. He received his PhD in molecular genetics from the University of California Irvine and was a postdoctoral fellow at the Whitehead Institute, MIT.
Annemieke Aartsma-Rus, PhD
Annemieke Aartsma-Rus is professor of translational genetics in the Department of Human Genetics at the Leiden University Medical Center (LUMC), and one of the most influential researchers in the field of Duchenne Muscular Dystrophy (DMD). Her research focuses on advancing therapeutic exon skipping for DMD into the clinic. Dr. Aartsma-Rus also serves as a scientific advisor for various DMD organizations. As a foremost expert in the field, Dr. Aartsma-Rus received the Duchenne Award from the Duchenne Parent Project for her dedication and research in DMD in 2011 and the Black Pearl Science Award from Eurordis in 2021. She received her PhD from Leiden University and was a postdoctoral fellow at the LUMC.
Philip Van Damme, MD
Philip Van Damme is professor of neurology at the University Hospitals in Leuven (Belgium), where he leads the Neuromuscular Reference Center. His current research focuses on genetic modifiers of amyotrophic lateral sclerosis (ALS) and disease pathways in pluripotent stem cell models derived from ALS patients. As a prominent medical expert in neurology, Dr. Van Damme has published over 200 papers in international peer-reviewed journals on ALS and related neuromuscular disorders, and he is the chair of the European Academy of Neurology (EAN) guideline panel on ALS. He holds an MD from KU Leuven University.
Hendrik Fuchs, PhD
Hendrik Fuchs is professor at the Institute for Laboratory Medicine, Clinical Chemistry, and Pathobiochemistry at the Charité – Universitätsmedizin Berlin in Germany. Dr. Fuchs has spent more than 20 years researching the development of protein-based targeted anti-tumor therapeutics and is widely recognized as a pioneer in the use of saponins for endosomal escape. He was the coordinator of a large European project on targeted gene delivery and has published over 100 peer-reviewed articles. He holds a PhD from Free University of Berlin.
About Sapreme
Sapreme is developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as PMOs, ASOs and siRNAs to intracellular targets in extrahepatic tissues as well as the liver. We have successfully translated the technology to non-human primates and have obtained in vivo PoCs in muscle, heart, kidney and tumor tissue. Sapreme is now building a broader pipeline to address high unmet needs in neuromuscular, renal, cardiometabolic diseases and beyond. Our lead candidate is designed as best-in-class in Duchenne Muscular Dystrophy and we are pursuing strategic partnerships to co-develop product candidates with selected pharma/biotech companies based on our endosomal escape platform.
